2026 Half‑Year Research Report

Executive Summary

This half‑year research report outlines core progress from Chlovelxy research laboratories across the first six months of 2026, centering on joint‑targeted transdermal formulation innovation, optimizations to penetration‑enhancing dissolvable microneedle architecture, comprehensive laboratory validation datasets, risk assessment, and the revised full‑year product development roadmap. Driven by the founder’s lived experience of severe rheumatoid arthritis and lower‑limb tissue necrosis, Chlovelxy’s research mission remains rooted in solving unmet daily joint care needs for millions of people who struggle with chronic joint discomfort, inflammatory stiffness and activity‑related joint strain, while avoiding the common downsides of oral analgesics, superficial topical creams and invasive intra‑articular injections.

During H1‑2026, the R&D team delivered meaningful formulation breakthroughs. The upgraded penetration‑enhancing microneedle platform completed repeated rounds of in‑vitro permeation testing, mechanical stability verification, biocompatibility screening and accelerated stability chamber trials, achieving consistent, repeatable lab‑test performance. This report documents technical challenges overcome, key experimental outcomes, existing technical limitations, risk considerations for real‑world usage, and the updated full‑year product roadmap that translates laboratory achievements toward consumer‑ready joint care solutions. While promising laboratory data has been obtained, all work described represents pre‑market laboratory‑scale research, and does not constitute medical claims or clinical treatment conclusions.

1. Introduction: The Real‑World Pain Point That Guides Formulation Development

Globally, hundreds of millions of adults live with recurring joint‑related discomfort ranging from morning stiffness after rest, exercise‑induced joint strain, osteoarthritis‑related swelling and tenderness, to chronic inflammatory joint conditions. Existing mainstream solutions carry well‑documented compromises. Oral anti‑inflammatory and analgesic agents pass through gastrointestinal metabolism, creating digestive intolerance for large groups of users. Conventional topical gels, ointments and patches predominantly remain on the outer stratum corneum layer of skin, with very limited active ingredient penetration toward deep peri‑joint soft tissue. Intra‑articular injections can deliver high local concentrations but require repeated clinical visits and bring procedural risks, making them unsuitable for routine home‑based daily management.

Chlovelxy originated from personal suffering. Our founder experienced advanced rheumatoid arthritis that progressed to lower‑limb tissue necrosis and complete loss of independent mobility. Enduring years of limited treatment options, he set out to build a research‑driven brand: to create accessible home‑use technology so fewer people would endure the same disabling joint decline he experienced. This human‑centered mission defines every R&D decision. Instead of pursuing short‑term cosmetic marketing effects, the laboratory prioritizes transdermal delivery that can reliably transport active compounds past skin barriers toward joint‑adjacent tissue, with good skin tolerability and simple at‑home application.

Traditional dissolvable microneedle designs face well‑known technical bottlenecks which became our primary research targets in H1‑2026. Common pain points include inconsistent mechanical piercing performance across different skin elasticity; premature tip dissolution before reaching target tissue depth; uneven active‑agent distribution inside needle arrays; poor patch adhesion on curved joint surfaces such as knees, elbows and ankles; and stability degradation during temperature fluctuation storage and transportation. Our half‑year work focused on mitigating these failure modes, building a penetration‑enhancing microneedle system tailored specifically for joint anatomy.

2. H1‑2026 Core Research Direction: Joint‑Targeted Formulation & Penetration‑Enhancing Microneedle Platform

Two tightly connected research streams advanced in parallel: joint‑optimized active‑ingredient formulation engineering, and the penetration‑enhancing dissolvable microneedle physical delivery platform.

2.1 Joint‑targeted formulation iteration work

The formulation team focused on a composite system built around high‑molecular‑weight hyaluronic acid, chondroitin sulfate, and selected plant‑derived anti‑inflammatory co‑factors, balanced for compatibility with dissolvable microneedle tip matrices. Not every bioactive compound can be integrated into microneedle structures: many molecules degrade during vacuum drying manufacturing, or interfere with polymer cross‑linking and reduce needle mechanical strength.

Over H1, 17 variant formulation batches were prepared and screened. Early batches showed two major defects. First, high loading of chondroitin sulfate weakened needle tip mechanical strength, causing tips to crumble under standard penetration‑force testing. Second, certain plant‑derived components accelerated premature dissolution of needle tips before sufficient skin micro‑channel creation. By adjusting multi‑polymer ratio combinations of PVP, hyaluronic acid and modified dextran, and implementing a two‑stage vacuum temperature‑ramped drying manufacturing workflow, researchers arrived at Batch F‑11‑04 as the lead candidate formulation. This lead formulation maintains bio‑activity of key functional ingredients while preserving the mechanical integrity required for skin penetration, and avoids undesirable skin‑irritating excipients.

2.2 Advanced penetration‑enhancing microneedle architecture upgrades

Building upon standard dissolvable microneedle templates, engineering upgrades were implemented for joint‑area usage. The array geometry was adjusted from uniform vertical pyramids to slightly tapered tip profiles optimized for curved joint skin surfaces. Needle height was calibrated to reach across the stratum corneum into upper dermis without reaching deep nociceptive nerve layers, pursuing low‑pain application experience. Array density and spacing were recalculated for knee, shoulder and ankle anatomical curvature, improving patch conformal contact.

A key technical upgrade is the layered tip‑core‑backing structure. The tip layer concentrates high‑priority active ingredients; the transition core layer controls dissolution kinetics to prevent overly fast or overly slow breakdown; the flexible backing layer improves adherence on flexing joint surfaces during movement. This layered architecture separates different functional materials physically, solving many incompatibility challenges that troubled single‑material microneedle prototypes.

3. Summary of H1‑2026 Laboratory Test Performance

Multiple test suites were completed including mechanical penetration testing, ex‑vivo skin permeation studies, accelerated stability testing, cell‑level biocompatibility screening and dissolution‑kinetics measurement. All tests followed standardized laboratory operating protocols, with multiple parallel sample replicates for statistical confidence.

• Mechanical penetration performance：Universal mechanical tester measured compression‑penetration force. Lead prototype arrays achieved consistent penetration force threshold meeting target specification. Under test conditions simulating human skin elasticity, over 94% of microneedle tips maintained intact geometry upon penetration, greatly improved compared to earlier H0‑2025 prototypes averaging only 71% intact tip retention. This reduction in tip fracture risk is critical: broken residual material inside skin represents a major safety risk for microneedle consumer products.
• Ex‑vivo permeation testing：Franz diffusion cell equipment using excised porcine skin model evaluated transdermal delivery efficiency. Comparative groups included conventional topical gel and our microneedle patch prototype. The microneedle system demonstrated markedly higher cumulative transdermal delivery of target actives versus gel‑form control samples. The test also confirmed sustained release profile: initial rapid release phase within the first 15‑30 minutes after patch application, followed by extended gradual release across multiple hours, which aligns with the intended use scenario for overnight joint patch wear.
• Dissolution kinetics：After skin insertion simulation, needle tips achieved substantial dissolution within 12‑20 minutes, matching design expectations. Complete dissolution eliminates requirement for needle removal, which is essential for consumer‑friendly home‑use experience.
• Accelerated stability chamber trials：Prototype patches were placed under controlled accelerated conditions (40℃ / 75% relative humidity) for 90‑day testing to simulate long‑term storage and logistics temperature stress. Periodic sampling checked needle morphology, active‑ingredient retention rate and dissolution behavior. The lead candidate retained high percentage of active‑ingredient content, without visible needle warping or brittling. This result demonstrates feasibility for normal supply‑chain circulation, though real‑world long‑term shelf‑life testing under ambient conditions will continue through H2‑2026.
• In‑vitro biocompatibility screening：Human dermal fibroblast cell testing showed low cytotoxicity profile for lead formulation extracts. No strong pro‑inflammatory marker elevation was observed under experimental conditions. This provides preliminary confidence for skin safety, while noting cell‑level results cannot fully replace human skin irritation patch testing which remains scheduled for next‑phase work.

Important limitations must be clearly stated. These are laboratory‑scale results. Ex‑vivo skin models cannot perfectly replicate complex living human tissue environment. Real‑world performance will be influenced by individual skin thickness, age, local skin hydration status, joint movement during patch wear and many other variables. No human clinical trial outcomes are available at this half‑year milestone.

4. Technical Risks & Identified Remaining Challenges

R&D teams documented unresolved technical hurdles that will occupy H2‑2026 resources.

First, sweat and joint‑area skin movement still threaten patch adhesion. During vigorous limb movement or heavy perspiration, partial edge lifting may occur. Material science work on improved pressure‑sensitive adhesive layers will continue.

Second, inter‑person skin variability creates performance deviation. Thicker calloused skin on knees of some users may reduce penetration consistency. Future iteration will explore minor‑variant patch options for different skin‑condition scenarios.

Third, manufacturing scaling risk. Laboratory small‑batch manual casting yields excellent specimens, but mass‑production high‑volume molding must maintain array uniformity across millions of units. Process‑engineering transfer to pilot‑scale manufacturing lines is a critical upcoming gate.

Fourth, sensory user‑experience optimization. Even minimally‑invasive microneedles produce mild transient micro‑puncture marks on skin. Research must balance delivery performance with minimizing visible temporary skin marks for everyday consumers.

These challenges are not failures of the H1 breakthrough, but realistic engineering barriers on the path from lab innovation toward finished consumer product.

5. Updated Full‑Year 2026 Product Roadmap (Revised June 2026)

Building upon H1 stable lab‑test performance, Chlovelxy R&D has updated the full‑year roadmap with clear phase gates, milestones and go‑no‑go evaluation check‑points.

Internal go‑no‑go rules are enforced. If pilot‑batch consistency or human‑relevant safety indicators fail preset thresholds, product launch timelines will be extended to allow further formulation rework. Speed‑to‑market will never override safety standards.

6. Mission Alignment: Lab Innovation Serving Real‑World People

Every technical parameter in this microneedle program traces back to human‑centered starting point: our founder’s personal battle with crippling joint disease. He experienced how limited treatment choices can trap people in reduced mobility and lowered quality‑of‑life. Chlovelxy’s research ambition is not to create a “miracle technology”, but to build accessible home‑use alternatives that fill gaps left by creams, oral pills and hospital injections.

Millions of people cannot attend frequent clinical injection appointments. Many cannot tolerate oral joint‑care medication due to stomach sensitivity. Others try dozens of topical products only to find actives never reach deep joint tissue. Our laboratory progress in H1‑2026 moves us closer toward giving these users another practical option. It remains critical to manage expectations: laboratory success does not equal finished commercial product. Multiple hard engineering and safety gates still lie ahead before consumers can purchase this microneedle joint patch.

The brand R&D philosophy separates marketing narrative from laboratory reality. Internal research reports are designed to record both positive results and failures, defects and unknown variables. Transparent internal documentation helps prevent over‑hyping early‑stage innovation before real‑world validation is complete.

7. Conclusion

During the first half of 2026, Chlovelxy R&D achieved meaningful breakthroughs for joint‑targeted formulation research. The advanced penetration‑enhancing dissolvable microneedle delivery platform delivered stable, repeatable performance across multiple laboratory testing workflows including mechanical penetration, ex‑vivo permeation, dissolution kinetics and accelerated stability assessment. Significant technical challenges still remain around scaling manufacturing, joint‑surface patch adhesion, human‑subject safety evaluation and real‑world performance variability.

Based on these half‑year outcomes, the team has published the updated full‑year 2026 product roadmap, establishing clear phase‑milestones and go‑no‑go decision gates to guide translation from lab prototypes toward consumer‑ready joint‑care solutions. Rooted in the founder’s personal experience of severe joint disability, the entire research program keeps focus on solving genuine unmet user needs, prioritizing safety, reproducibility and real‑world usability over premature commercialization. Further data generation in H2‑2026 will determine the actual timeline for market introduction of Chlovelxy microneedle joint patch products.